title: [Expression of LATS mRNA in mantle cell lymphoma and its clinical significance].
abstract: OBJECTIVE
  To investigate the expression level of large tumor suppressor (LATS)1, LATS2 mRNA and its prognostic value in mantle cell lymphoma (MCL).
  
  
  METHODS
  A total of 36 B-NHL cases (including MCL 16 cases, chronic lymphoblastic leukemia (CLL) 11 cases, splenic marginal zone cell lymphoma (SMZL) 9 cases) and 8 healthy donors were enrolled in this study from January 2008 to April 2011 in our Lymphoma Clinic Center. The mRNA level of Yap (effector of Hippo pathway) and LATS1, LATS2 mRNA were detected by using real-time quantitative PCR. Log expression values of real-time quantitative PCR data were used in this analysis.
  
  
  RESULTS
  The YAP mRNA expression level in MCL, CLL and SMZL patient were significantly higher than that in health donor (lg: 1.97±0.79, 1.83±0.54, 2.12±0.42 vs 1.21±1.56, all P<0.05). The expression level of LATS1, LATS2 mRNA in MCL was significantly correlated with molecular cytogenetic aberrations, progression free survival (PFS) and overall survival (OS). The LATS1 expression level was statistically lower in the group of MCL with delection P53 than the group of MCL without delection P53 (lg: 0.75±0.27 vs 1.10±0.19, P=0.035). And the LATS1 expression level was statistically lower in the death group than the survival group (lg: 0.76±0.27 vs 1.15±0.17, P=0.026). The PFS and OS were significantly longer in the MCL patients with high level of LATS1 than that of other MCL patients ((70.4±32.7) vs (5.6±2.2) months, P=0.044; (123.8±22.0) vs (7.7±2.2) months, P=0.017).
  
  
  CONCLUSIONS
  Hippo pathway is dysfunctional in B-NHL, especially in MCL.The reduced expression of LATS1, LATS2 in MCL patients is associated with progressive disease, and might be an important prognostic factor in MCL.
authors.affiliation: Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin 300020, China.
authors.forename: Zhen
authors.initials: Z
authors.lastname: Yu
authors.affiliation: Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin 300020, China.
authors.forename: Shuhua
authors.initials: S
authors.lastname: Yi
authors.affiliation: Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin 300020, China.
authors.forename: Yanru
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin 300020, China.
authors.forename: Zengjun
authors.initials: Z
authors.lastname: Li
authors.affiliation: Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin 300020, China; Email: qiulg@ihcams.ac.cn.
authors.forename: Lugui
authors.initials: L
authors.lastname: Qiu
mesh_terms: D018572:Disease-Free Survival; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell; D020522:Lymphoma, Mantle-Cell; D011379:Prognosis; D017346:Protein Serine-Threonine Kinases; D012333:RNA, Messenger; D025521:Tumor Suppressor Proteins
chemical_list: D012333:RNA, Messenger; D025521:Tumor Suppressor Proteins; C092745:LATS1 protein, human; C406449:LATS2 protein, human; D017346:Protein Serine-Threonine Kinases